NCT03291444View on ClinicalTrials.gov

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 5, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

June 1, 2025

Conditions
Leukemia, Acute Lymphocytic (ALL)Leukemia, Acute Myelogenous (AML)Myelodysplastic Syndromes
Interventions
BIOLOGICAL

Chimeric antigen receptor T cells

After pretreatment, chimeric antigen receptor T cells will be transfused.

BIOLOGICAL

peptide specific dendritic cell

After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.

Trial Locations (1)

510282

RECRUITING

Zhujiang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Geno-Immune Medical Institute

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

lead

Zhujiang Hospital

OTHER